

# Guidance for Industry and Reviewers

## Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers

### *DRAFT GUIDANCE*

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Robert Osterberg, 301-594-5476 or (CBER) Martin Green 301-827-5349.

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)  
December 2002  
Pharmacology and Toxicology

<http://www.fda.gov/OHRMS/DOCKETS/98fr/02d-0492-gdl0001-vol1.doc>  
09/05/13



DTX-1252-0001

Dr. Reddy's Laboratories, Ltd., et al.  
v.

# Guidance for Industry and Reviewers

## Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers

*Additional copies are available from:*

*Office of Training and Communications  
Division of Drug Information, HFD-240  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857  
(Tel) 301-827-4573*

*<http://www.fda.gov/cder/guidance/index.htm>  
or*

*Office of Communication, Training and  
Manufacturers Assistance (HFMA-40)  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
1401 Rockville Pike  
Rockville, MD 20852-1448*

*(Internet) <http://www.fda.gov/cber/guidelines.htm>*

*Mail: The Voice Information System at 800-835-4709 or 301-827-1800*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)  
December 2002  
Pharmacology and Toxicology**

<http://www.fda.gov/OHRMS/DOCKETS/98fr/02d-0492-gdl0001-vol1.doc>  
09/02/13

## Table of Contents

<b>I. INTRODUCTION.....</b>	<b>1</b>
<b>II. SCOPE .....</b>	<b>1</b>
<b>III. OVERVIEW OF THE ALGORITHM .....</b>	<b>3</b>
<b>IV. STEP 1: NO OBSERVED ADVERSE EFFECT LEVEL (NOAEL) DETERMINATION .....</b>	<b>4</b>
<b>V. STEP 2: HUMAN EQUIVALENT DOSE (HED) CALCULATION.....</b>	<b>5</b>
<b>A. Conversion Based on Body Surface Area .....</b>	<b>5</b>
<b>B. Basis for Using Mg/Kg Conversions.....</b>	<b>7</b>
<b>C. Other Exceptions to Mg/M<sup>2</sup> Scaling Between Species .....</b>	<b>8</b>
<b>VI. STEP 3: MOST APPROPRIATE SPECIES SELECTION.....</b>	<b>8</b>
<b>VII. STEP 4: APPLICATION OF SAFETY FACTOR.....</b>	<b>9</b>
<b>A. Increasing the Safety Factor .....</b>	<b>10</b>
<b>B. Decreasing the Safety Factor .....</b>	<b>11</b>
<b>VIII. STEP 5: CONSIDERATION OF THE PHARMACOLOGICALLY ACTIVE DOSE (PAD).....</b>	<b>11</b>
<b>IX. SUMMARY .....</b>	<b>12</b>
<b>REFERENCES.....</b>	<b>13</b>
<b>APPENDIX A.....</b>	<b>15</b>
<b>APPENDIX B .....</b>	<b>17</b>
<b>APPENDIX C .....</b>	<b>22</b>
<b>APPENDIX D.....</b>	<b>23</b>
<b>APPENDIX E .....</b>	<b>25</b>
<b>GLOSSARY.....</b>	<b>26</b>

1  
2 **Guidance for Industry and Reviewers<sup>1</sup>**  
3  
4

5 **Estimating the Safe Starting Dose in Clinical Trials**  
6 **for Therapeutics in Adult Healthy Volunteers**  
7  
8

9  
10 This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current  
11 thinking on this topic. It does not create or confer any rights for or on any person and does not operate to  
12 bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements  
13 of the applicable statutes and regulations.  
14

15  
16  
17 **I. INTRODUCTION**  
18

19 This guidance outlines a process (algorithm) and vocabulary for deriving the maximum  
20 recommended starting dose (MRSD) for "first in human" clinical trials of new molecular entities  
21 in adult healthy volunteers and recommends a standardized process by which the MRSD can be  
22 selected. The purpose of this process is to ensure the safety of the human volunteers.  
23

24 The goals of this guidance are to (1) establish a consistent terminology for discussing the starting  
25 dose, (2) provide common conversion factors for deriving a human equivalent dose, and (3)  
26 delineate a strategy for selecting the MRSD for adult healthy volunteers, regardless of the  
27 projected clinical use. This process is diagrammed with a flow chart that presents the decisions  
28 and calculations used to generate the MRSD from animal data.  
29  
30

31 **II. SCOPE**  
32

33 The process identified in this document pertains to determining the MRSD for adult healthy  
34 subjects when beginning a clinical investigation of any new drug or biological therapeutic that  
35 has been studied in animals. This document is not pertinent to prophylactic vaccines or  
36 endogenous proteins (i.e., recombinant clotting factors) used at physiologic concentrations. The  
37 process outlined in this document does not address dose escalation or maximum allowable doses  
38 in clinical trials.  
39

---

<sup>1</sup> This guidance has been prepared by the Office of New Drugs in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.



40 Although the process outlined in this document uses observed toxicities, administered doses, and  
41 an algorithmic approach to calculate the MRSD, an alternative approach could be proposed that  
42 places primary emphasis on animal pharmacokinetics and modeling rather than dose. In a  
43 limited number of cases, animal pharmacokinetic data may be useful in determining initial  
44 clinical doses.<sup>2</sup> However, in the majority of new INDs, animal data are not available in  
45 sufficient detail to construct a scientifically valid, pharmacokinetic model whose aim is to  
46 accurately project an MRSD.

47  
48 Toxicity should be avoided at the initial dose. However, doses should be chosen that allow  
49 reasonably rapid attainment of the phase I trial objectives (e.g., assessment of the therapeutic's  
50 tolerability, pharmacodynamic or pharmacokinetic profile). All of the relevant preclinical data,  
51 including information on the pharmacologically active dose, the full toxicologic profile of the  
52 compound, and the pharmacokinetics (absorption, distribution, metabolism, and excretion) of the  
53 therapeutic, should be considered when determining the MRSD. Starting with doses lower than  
54 the MRSD is always a possible option and may be particularly appropriate to meet some clinical  
55 trial objectives.

56  
57 The remainder of this document will focus on the recommended algorithmic process for starting  
58 dose extrapolation from animals to humans based on administered doses, since this method will  
59 likely be useful for the majority of new INDs seeking to investigate new drugs in healthy  
60 volunteers. Some classes of drugs (e.g., many cytotoxic or biological agents) are commonly  
61 introduced into initial clinical trials in patient volunteers rather than healthy volunteers.  
62 Typically, this occurs when a drug is suspected or known to be unavoidably toxic. Although this  
63 document does not specifically address starting doses in patients, many principles and some  
64 approaches recommended here may be applicable to designing such trials.

65

---

<sup>2</sup> If the parent drug is measured in the plasma at multiple times and fits the range of toxic dose for two or more animal species, it may be possible to develop a pharmacokinetic model predicting human doses and concentrations and draw inferences about human safe plasma levels in the absence of prior human data. While quantitative modeling for this purpose may be straightforward, the following points suggest this approach may present a number of difficulties when evaluating estimates of a safe starting dose. Generally, at the time of IND initiation, there are a number of unknowns regarding animal toxicity and comparability of human and animal pharmacokinetics and metabolism: (1) human bioavailability and metabolism may differ significantly from that of animals; (2) mechanisms of toxicity may not be known (i.e., toxic accumulation in a peripheral compartment; and/or (3) toxicity may be due to an unidentified metabolite, not parent drug. Thus, to rely on pharmacokinetic models (based on parent drug in plasma) to gauge starting doses would require multiple untested assumptions. Modeling may be used with greatest validity to estimate human starting doses in special cases where few underlying assumptions would be necessary. Such cases are exemplified by large molecular weight proteins (like humanized monoclonal antibodies), which are intravenously administered, are removed from circulation by endocytosis rather than metabolism, have immediate and detectable effects on blood cells, and have a volume of distribution limited to the plasma volume. Here, allometric, pharmacokinetic, and pharmacodynamic models have been useful in identifying the human mg/kg dose that would be predicted to correlate with safe drug plasma levels in nonhuman primates. Even in these cases, uncertainties (such as differences between human and chimpanzee receptor sensitivity or density) have been shown to affect human pharmacologic or toxicologic outcomes, and the use of safety factors as described in this document is still warranted.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.